FibroBiologics’ (FBLG) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of FibroBiologics (NASDAQ:FBLG) in a research note published on Monday morning,Benzinga reports. They currently have a $15.00 target price on the stock.

FBLG has been the topic of a number of other reports. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of FibroBiologics in a report on Friday, September 12th. Weiss Ratings reissued a “sell (e+)” rating on shares of FibroBiologics in a report on Wednesday, October 8th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $12.33.

FibroBiologics Trading Up 13.2%

NASDAQ FBLG opened at $0.37 on Monday. The stock’s 50 day moving average is $0.50 and its 200 day moving average is $0.67. FibroBiologics has a 12 month low of $0.32 and a 12 month high of $3.89. The stock has a market cap of $19.06 million, a PE ratio of -0.77 and a beta of -0.72.

FibroBiologics (NASDAQ:FBLG) last posted its quarterly earnings results on Friday, October 31st. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.03). On average, analysts forecast that FibroBiologics will post -0.53 EPS for the current fiscal year.

Institutional Trading of FibroBiologics

Large investors have recently added to or reduced their stakes in the company. AQR Capital Management LLC bought a new stake in FibroBiologics in the 1st quarter worth approximately $29,000. Nuveen LLC bought a new stake in FibroBiologics in the 1st quarter worth approximately $31,000. XTX Topco Ltd increased its stake in FibroBiologics by 160.0% in the 2nd quarter. XTX Topco Ltd now owns 45,945 shares of the company’s stock worth $29,000 after acquiring an additional 28,276 shares during the last quarter. Ethos Financial Group LLC increased its stake in FibroBiologics by 100.0% in the 2nd quarter. Ethos Financial Group LLC now owns 48,848 shares of the company’s stock worth $30,000 after acquiring an additional 24,424 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd bought a new stake in FibroBiologics in the 2nd quarter worth approximately $37,000.

FibroBiologics Company Profile

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.